Celgene Corporation (NASDAQ:CELG) had its price target decreased by SunTrust Banks, Inc. from $156.00 to $127.00 in a research report report published on Friday morning. SunTrust Banks, Inc. currently has a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts have also recently issued reports on CELG. Cantor Fitzgerald cut shares of Celgene Corporation from an overweight rating to a neutral rating in a report on Friday. Robert W. Baird reissued a hold rating and issued a $103.00 price target on shares of Celgene Corporation in a report on Friday. Oppenheimer Holdings, Inc. reissued an outperform rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Wednesday, August 9th. Royal Bank Of Canada lowered their price target on shares of Celgene Corporation from $166.00 to $148.00 and set a top pick rating on the stock in a report on Friday. Finally, Piper Jaffray Companies reissued a neutral rating and issued a $133.00 price target on shares of Celgene Corporation in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of Buy and an average price target of $141.44.
Celgene Corporation (CELG) traded down 1.82% during trading on Friday, reaching $98.17. The company’s stock had a trading volume of 24,135,277 shares. The company has a market cap of $76.80 billion, a P/E ratio of 30.40 and a beta of 1.88. The company’s 50 day moving average price is $136.88 and its 200 day moving average price is $129.95. Celgene Corporation has a 52 week low of $94.55 and a 52 week high of $147.17.
Celgene Corporation (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 68.62%. Celgene Corporation’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.58 EPS. On average, equities analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.
WARNING: “Celgene Corporation (CELG) Given New $127.00 Price Target at SunTrust Banks, Inc.” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2017/10/29/celgene-corporation-celg-given-new-127-00-price-target-at-suntrust-banks-inc.html.
In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ernest Mario sold 18,506 shares of Celgene Corporation stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders have sold 46,233 shares of company stock valued at $6,268,259 over the last quarter. Corporate insiders own 0.95% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in CELG. Thompson Davis & CO. Inc. boosted its holdings in Celgene Corporation by 5.9% during the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Arcadia Investment Management Corp MI boosted its holdings in Celgene Corporation by 118.7% during the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Celgene Corporation during the first quarter worth about $118,000. Guidant Wealth Advisors purchased a new position in Celgene Corporation during the third quarter worth about $119,000. Finally, Motco boosted its holdings in Celgene Corporation by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the last quarter. Institutional investors and hedge funds own 79.23% of the company’s stock.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Celgene Corporation and related companies with MarketBeat.com’s FREE daily email newsletter.